{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:27:50Z","timestamp":1786994870599,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.neurol.2018.06.002","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T10:47:55Z","timestamp":1532429275000},"page":"515-521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["French consensus: Treatment of newly diagnosed restless legs syndrome"],"prefix":"10.1016","volume":"174","author":[{"given":"N.","family":"Limousin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Flamand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Charley Monaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2018.06.002_bib0165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.sleep.2016.06.021","article-title":"Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome","volume":"25","author":"Cho","year":"2016","journal-title":"Sleep Med"},{"key":"10.1016\/j.neurol.2018.06.002_bib0170","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.sleep.2011.06.009","article-title":"Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial","volume":"12","author":"Allen","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.neurol.2018.06.002_bib0175","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.sleep.2006.03.011","article-title":"Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study\u2014The PRELUDE study","volume":"7","author":"Partinen","year":"2006","journal-title":"Sleep Med"},{"key":"10.1016\/j.neurol.2018.06.002_bib0180","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.sleep.2008.09.001","article-title":"Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial","volume":"9","author":"Ferini-Strambi","year":"2008","journal-title":"Sleep Med"},{"key":"10.1016\/j.neurol.2018.06.002_bib0185","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/mds.20983","article-title":"Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome","volume":"21","author":"Trenkwalder","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.06.002_bib0190","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.sleep.2010.08.005","article-title":"Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood","volume":"12","author":"Montagna","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.neurol.2018.06.002_bib0195","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.sleep.2010.12.007","article-title":"Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome","volume":"12","author":"H\u00f6gl","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.neurol.2018.06.002_bib0200","article-title":"The treatment of restless legs syndrome and periodic limb movement disorder in adults\u2014an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses","author":"Aurora","year":"2012","journal-title":"Sleep"},{"key":"10.1016\/j.neurol.2018.06.002_bib0205","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1468-1331.2012.03853.x","article-title":"European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society","volume":"19","author":"Garcia-Borreguero","year":"2012","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2018.06.002_bib0210","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.sleep.2007.04.010","article-title":"Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe","volume":"9","author":"Oertel","year":"2008","journal-title":"Sleep Med"},{"key":"10.1016\/j.neurol.2018.06.002_bib0215","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(08)70112-1","article-title":"Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Trenkwalder","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2018.06.002_bib0220","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.sleep.2010.02.014","article-title":"Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study","volume":"11","author":"Oertel","year":"2010","journal-title":"Sleep Med"},{"key":"10.1016\/j.neurol.2018.06.002_bib0225","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.sleep.2008.04.012","article-title":"One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome","volume":"9","author":"Oertel","year":"2008","journal-title":"Sleep Med"},{"key":"10.1016\/j.neurol.2018.06.002_bib0230","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S1474-4422(11)70127-2","article-title":"Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study","volume":"10","author":"Oertel","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2018.06.002_bib0235","first-page":"81","article-title":"Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study","volume":"33","author":"Cornelius","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.neurol.2018.06.002_bib0240","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.parkreldis.2007.05.006","article-title":"Predictors of impulsivity and reward seeking behavior with dopamine agonists","volume":"14","author":"Ondo","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2018.06.002_bib0245","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/wnf.0b013e31804c780e","article-title":"Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome","volume":"30","author":"Driver-Dunckley","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.neurol.2018.06.002_bib0250","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2165\/00023210-200923020-00005","article-title":"Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management","volume":"23","author":"O\u02bcSullivan","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neurol.2018.06.002_bib0255","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.sleep.2011.09.013","article-title":"Efficacy and safety of dopamine agonists in restless legs syndrome","volume":"13","author":"Hornyak","year":"2012","journal-title":"Sleep Med"},{"key":"10.1016\/j.neurol.2018.06.002_bib0260","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1212\/WNL.59.10.1573","article-title":"Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study","volume":"59","author":"Garcia-Borreguero","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.06.002_bib0265","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000072882","article-title":"Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome","volume":"48","author":"Happe","year":"2003","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.neurol.2018.06.002_bib0270","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2012.746217","article-title":"Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study","volume":"29","author":"Inoue","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.neurol.2018.06.002_bib0275","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3109\/07853890.2015.1025825","article-title":"Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 trials of gabapentin enacarbil","volume":"47","author":"Bogan","year":"2015","journal-title":"Ann Med"},{"key":"10.1016\/j.neurol.2018.06.002_bib0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.sleep.2016.01.017","article-title":"Guidelines for the first-line treatment of restless legs syndrome\/Willis\u2013Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation","volume":"21","author":"Garcia-Borreguero","year":"2016","journal-title":"Sleep Med"},{"key":"10.1016\/j.neurol.2018.06.002_bib0285","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.sleep.2010.03.003","article-title":"A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome","volume":"11","author":"Allen","year":"2010","journal-title":"Sleep Med"},{"key":"10.1016\/j.neurol.2018.06.002_bib0290","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1212\/WNL.0b013e3181e1ce73","article-title":"Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study","volume":"74","author":"Garcia-Borreguero","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.06.002_bib0295","doi-asserted-by":"crossref","DOI":"10.5665\/sleep.3558","article-title":"Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome","author":"Garcia-Borreguero","year":"2014","journal-title":"Sleep"},{"key":"10.1016\/j.neurol.2018.06.002_bib0300","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1474-4422(13)70239-4","article-title":"Prolonged release oxycodone\u2013naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension","volume":"12","author":"Trenkwalder","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2018.06.002_bib0305","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/sleep\/16.4.327","article-title":"Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo","volume":"16","author":"Walters","year":"1993","journal-title":"Sleep"},{"key":"10.1016\/j.neurol.2018.06.002_bib0310","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1303646","article-title":"Comparison of pregabalin with pramipexole for restless legs syndrome","volume":"370","author":"Allen","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurol.2018.06.002_bib0315","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1053\/j.ajkd.2015.12.027","article-title":"Rotigotine in hemodialysis-associated restless legs syndrome: a randomized controlled trial","volume":"68","author":"Dauvilliers","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.neurol.2018.06.002_bib0320","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annfar.2010.09.002","article-title":"Implications anesth\u00e9siques du syndrome des jambes sans repos\u00a0: observations cliniques et recommandations pratiques","volume":"29","author":"Karroum","year":"2010","journal-title":"Ann Fr Anesth Reanim"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378718307082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378718307082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T13:02:46Z","timestamp":1534510966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378718307082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":32,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0035378718307082"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2018.06.002","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French consensus: Treatment of newly diagnosed restless legs syndrome","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2018.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}